A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women

Baytur, Yeşim Bülbül; Özbilgin, Kemal; Cilaker, Serap; Laçin, Selman; Kurtul, Ozgur; Oruç, Semra; Koyuncu, Faik Mümtaz

doi:10.1016/j.ejogrb.2006.07.042

Cited by 14 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This indicates that hypoestrogenemia mediated by GnRHa may have a differential functional activity in specific type of myoma through down-regulating either ER or PR. Similar decreased expression of ER/PR and Ki-67 in leiomyoma with consequent decrease of fibroid size has been reported elsewhere [12,35,57]. Our current findings of decreased ER/PR expression in response to leuprolide acetate confirmed the previous findings.…”

Section: Plos Onesupporting

confidence: 92%

Expression profiles of E/P receptors and fibrosis in GnRHa-treated and -untreated women with different uterine leiomyomas

et al. 2020

View full text Add to dashboard Cite

Differential expressions of estrogen/progesterone receptors (ER/PR) and individual component of extracellular matrices derived from fibroid are reported. Information on the pattern of change in ER/PR expression and amount of tissue fibrosis after hormonal treatment is unclear. We investigated pattern of change in ER/PR expression and percentage of tissue fibrosis in different uterine leiomyomas after gonadotropin-releasing hormone agonist (GnRHa) treatment. Biopsy specimens from fibroids and adjacent myometria were collected after surgery from women with submucosal myoma (SMM, n = 18), intramural myoma (IMM, n = 16) and subserosal myoma (SSM, n = 17). A proportion of women in each group of fibroid underwent treatment with GnRHa for a variable period of 3–6 months. Tissue expression of ER and PR was analyzed by immunohistochemistry. In vitro cell proliferation effect of GnRHa on human umbilical vein endothelial cells (HUVECs) was examined. Distribution of tissue fibrosis was examined by Masson’s trichrome staining with computer-captured image analysis of fibrosis derived from different types of fibroid. PR content was significantly higher than ER in tissues derived from GnRHa-untreated women with SMM and SSM (p = 0.04 for both). Comparing to untreated group, GnRHa-treatment significantly decreased either ER or PR expression in different fibroids. Exogenous treatment with GnRHa dose-dependently decreased proliferation of HUVECs. No significant difference was observed in the percentage of fibrosis in tissues collected from GnRHa-treated and -untreated women with fibroids. The distribution of fibrosis in myoma/myometria and occurrence of fibrosis in perivascular area showed an increasing trend with higher age of the women and with larger size of fibroids. Our findings suggest that despite estrogen dependency, higher PR content in GnRHa-untreated group may indicate a potential role of progesterone in leiomyoma growth. Although GnRHa therapy may shrink fibroids and reduce risk of bleeding during surgery, the occurrence of diffuse tissue fibrosis may impair effective reduction of fibroid size after hormonal treatment.

show abstract

Section: Plos Onesupporting

confidence: 92%

Expression profiles of E/P receptors and fibrosis in GnRHa-treated and -untreated women with different uterine leiomyomas

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Estrogens synthesized in leiomyoma cells boost proliferation, mainly due to stimulation of aromatase activity, the expression of www.fhc.viamedica.pl which is much higher in leiomyoma cells than in the tumor-surrounding smooth muscles. The presence of Ki-67 antigen outside the leiomyoma may indicate continuing hyperplasia of the tumor [20][21][22][23][24].…”

Section: Caspasementioning

confidence: 99%

Processes of apoptosis and cell proliferation in uterine myomas originating from reproductive and perimenopausal women

Plewka¹,

Plewka²,

Madej³

et al. 2011

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

P P P P Processes of apoptosis and cell proliferation in rocesses of apoptosis and cell proliferation in rocesses of apoptosis and cell proliferation in rocesses of apoptosis and cell proliferation in rocesses of apoptosis and cell proliferation in uterine myomas originating from uterine myomas originating from uterine myomas originating from uterine myomas originating from uterine myomas originating from reproductive and perimenopausal women reproductive and perimenopausal women reproductive and perimenopausal women reproductive and perimenopausal women reproductive and perimenopausal women We studied uterine myomas originating from females of reproductive age and from females of perimenopausal age. Uterine myomas represent benign tumors of the myometrium, and they develop frequently in women of reproductive age. The frequency of uterine myomas increases with age until women reach the menopause. The study included patients with a myomatous uterus, in the reproductive age or peri-menopausal age, independently evaluating small and large myomas. Myometrial alterations in their direct vicinity were evaluated independently of the myomas. The study included evaluation of immunolocalization of two index proteins which participate in myoma cells growth control: Ki-67 nuclear antigen and caspase 3. In women of reproductive age, both in small and large myomas, elevated immunostaining of Ki-67 was noted in parallel to low levels of caspase 3 staining, which indicated the ongoing process of proliferation. In women of peri-menopausal age with small or large myomas, no Ki-67 immunostaining was detected, while staining of caspase 3 manifested low levels. Proliferation in reproductive age women myomas is higher than in the peri-menopausal age. (Folia Histochemica et

show abstract

“…It was discovered that BCL-2 protein expression was rich in uterine myomas than normal myometrium. Abundant expression of BCL-2 protein in uterine myomas may be one of the mechanisms for the growth of uterine myomas11.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Inhibitory Effect of Gonadotropin Releasing Hormone (GnRH) Agonist, Selective Estrogen Receptor Modulator (SERM), Antiprogesterone on Myoma Cell Proliferation In Vitro

et al. 2014

View full text Add to dashboard Cite

Uterine myomas are the most common gynecologic tumor in women of reproductive age. Treatment options of uterine myomas consist of surgical, medical and interventional therapy such as uterine artery embolization or myolysis. Given that it is the most common type of tumor in women of reproductive age, the treatment of uterine myomas must prioritize uterine conservation. There are several drugs for medical treatment of uterine myoma such as gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM) and antiprogesterone. The objective of this study was to compare the effect of GnRH agonist, SERM, and antiprogesterone in the treatment of uterine myomas in vitro. The effect of drugs was evaluated through the cell viability assay in cultured leiomyoma cells, western blot analysis of proliferating cell nuclear antigen (PCNA), and BCL-2 protein expression. As a result, mifepristone single-treated group represents the most significant reduction in myoma cell viability and proliferation. When pretreated with leuprolide acetate, raloxifene shows more significant reduction in myoma cell viability and proliferation than mifepristone. This study suggests one of the possible mechanisms how medications act on uterine myoma, especially at the molecular level.

show abstract

A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women

Cited by 14 publications

References 38 publications

Expression profiles of E/P receptors and fibrosis in GnRHa-treated and -untreated women with different uterine leiomyomas

Expression profiles of E/P receptors and fibrosis in GnRHa-treated and -untreated women with different uterine leiomyomas

Processes of apoptosis and cell proliferation in uterine myomas originating from reproductive and perimenopausal women

Comparison of the Inhibitory Effect of Gonadotropin Releasing Hormone (GnRH) Agonist, Selective Estrogen Receptor Modulator (SERM), Antiprogesterone on Myoma Cell Proliferation In Vitro

Contact Info

Product

Resources

About